Skip to main content

Table 2 Withdrawal periods for maintenance and rescue therapies prior to V0, V1, and V4

From: The effects of benralizumab on airway geometry and dynamics in severe eosinophilic asthma: a single-arm study design exploring a functional respiratory imaging approach

Pharmaceutical class

Withdrawal period

SABAs

≥ 6 h

SAMAs

≥ 12 h

SAMA/SABA combinations

≥ 12 h

SMART/MART

≥ 12 h

1. SMART/MART reliever therapy and the use of (budesonide/formoterol) as a rescue therapy are permitted at investigator discretion

2. Total ICS dose resulting from permitted SMART/MART use must be recorded

LABA-containing therapies

1. Once daily: ≥ 24 h

2. Twice daily: ≥ 12 h

LAMA-containing therapies

1. Once daily: ≥ 24 h

2. Twice daily: ≥ 12 h

LTRAs

≥ 24 h

Theophyllines

1. Once daily: ≥ 24 h

2. Twice daily: ≥ 12 h

  1. ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, LTRA leukotriene receptor antagonist, MART maintenance and reliever therapy, SABA short-acting β2-agonist, SAMA short-acting muscarinic antagonist, SMART single maintenance and reliever therapy, V visit